What are the most common side effects of COBICISTAT?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for COBICISTAT. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is COBICISTAT the same as Tybost?

Tybost is a brand name for COBICISTAT. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

COBICISTAT

Q: What is COBICISTAT used for?

COBICISTAT (brand name Tybost) is a Other indicated for fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not recommended with darunavir 600 mg twice daily.

Q: How does COBICISTAT work?

COBICISTAT works through the following mechanism: 12.1 Mechanism of Action Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A). Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir..

Other

Brand names: Tybost

Oral

Mechanism of Action

12.1 Mechanism of Action Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A). Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir.

Indications

fosamprenavir

saquinavir

or tipranavir due to lack of exposure data. The use of TYBOST is not recommended with darunavir 600 mg twice daily

fosamprenavir

saquinavir

or tipranavir. ( 1.2

Contraindications

• phenobarbital
• phenytoin Anti-gout: colchicine Antimycobacterial: rifampin Antineoplastics: irinotecan These contraindications apply only to TYBOST coadministered with atazanavir Antipsychotics: lurasidone
• pimozide Ergot Derivatives: dihydroergotamine
• ergotamine
• methylergonovine Herbal Products: St. John's wort ( Hypericum perforatum ) Hormonal Contraceptives: drospirenone/ ethinyl estradiol Lipid-modifying Agents: lomitapide

FDA Warnings

5 WARNINGS AND PRECAUTIONS Assess creatinine clearance (CLcr) before initiating treatment
Monitor serum phosphorus in patients with or at risk for renal impairment
Measure serum phosphorus in patients with or at risk for renal impairment when used with TDF
3 Risk of Serious Adverse Reactions or Loss of Virologic Response Due to Drug Interactions Initiation of TYBOST, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A, or initiation of medications metabolized by CYP3A in patients already receiving TYBOST, may increase plasma concentrations of medications metabolized by CYP3A and reduce plasma concentrations of active metabolite(s) formed by CYP3A

Known Side Effects

1 documented side effects by frequency

Anxiety

1-10%

Community Discussions

No community discussions found for COBICISTAT yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → COBICISTAT openFDA label JSON → COBICISTAT FAERS adverse-event reports → COBICISTAT ClinicalTrials.gov → completed Phase 2+ trials of COBICISTAT

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral